ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0204

Making Rheum for Palliative Care in Rheumatology: Perspectives of Rheumatology and Palliative Care Clinicians

Health Services Research – ACR/ARP Poster I

10:30AM-12:30PM: Abstract Number: 0433

Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study

Reproductive Issues in Rheumatic Disorders Poster

10:30AM-12:30PM: Abstract Number: 0726

Management of ANCA Vasculitis-Associated Orbital Inflammatory Disease: A Systematic Literature Review

Vasculitis – ANCA-Associated Poster I

10:30AM-12:30PM: Abstract Number: 0516

Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old

RA – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0361

Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0307

Mean Metacarpophalangeal Extension to Clinically Quantify Flexor Fibro-inflammatory Hand Involvement in Diabetes

Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0342

Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0541

Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0635

Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients

SLE – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0277

Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0457

Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0101

Metabolomic Profiling Reveals a Role for Citric Acid Cycle Dysfunction in Antiphospholipid Syndrome Neutrophils

Antiphospholipid Syndrome Poster

10:30AM-12:30PM: Abstract Number: 0404

Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData

Pediatric Rheumatology – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0131

Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study

Epidemiology & Public Health Poster I

10:30AM-12:30PM: Abstract Number: 0075

Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis

SpA Including PsA – Basic Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].